COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03353753
Recruitment Status : Active, not recruiting
First Posted : November 27, 2017
Last Update Posted : September 16, 2019
Information provided by (Responsible Party):
Deciphera Pharmaceuticals LLC

Brief Summary:
This is a 2‑arm, randomized, placebo-controlled, double‑blind, international, multicenter study comparing the efficacy of DCC-2618 to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients will be randomized in a 2:1 ratio to DCC‑2618 150 mg QD or placebo

Condition or disease Intervention/treatment Phase
Gastrointestinal Stromal Tumors Drug: DCC-2618 Drug: Placebo Oral Tablet Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 129 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies
Actual Study Start Date : February 27, 2018
Actual Primary Completion Date : May 31, 2019
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Active Comparator: Arm 1
150 mg QD DCC-2618
Drug: DCC-2618
Oral KIT/PDGFRA kinase inhibitor
Other Name: ripretinib

Placebo Comparator: Arm 2
Drug: Placebo Oral Tablet

Primary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: 15 months ]
    PFS Based on independent radiologic review using modified RECIST

Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: 15 months ]
    Objective response rate as determined by confirmed CR + confirmed PR by independent radiologic review

  2. Time to Tumor Progression (TTP) based on independent radiologic review [ Time Frame: 15 months ]
    TTP based on independent radiologic review

  3. Overall Survival (OS) [ Time Frame: 15 months ]
  4. Time to best response [ Time Frame: 15 months ]
    Time to best response, as defined by the independent radiologic review,

  5. Progression Free Survival (PFS) [ Time Frame: 15 months ]
    PFS based on investigator assessment

  6. Quality of Life [ Time Frame: 18 months ]
    Changes from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer 30‑item and EuroQol 5-Dimension 5-Level

  7. Disease control rate (DCR) [ Time Frame: 12 weeks ]
    DCR as determined by complete response [CR] + partial response [PR] + stable disease

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologic diagnosis of GIST
  2. Patients must have progressed on imatinib, sunitinib, and regorafenib or have documented intolerance to any of these treatments.
  3. ECOG PS of 0 to 2 at screening.
  4. Able to provide an archival tumor tissue sample if no anticancer therapy was administered since the sample was collected; otherwise, a fresh tumor tissue sample is required prior to the first dose of study drug.
  5. Female patients of childbearing potential must have a negative serum beta‑human chorionic gonadotrophin (β-hCG) pregnancy test at screening and negative urine pregnancy test at Cycle 1 Day 1 prior to the first dose of study drug.
  6. Patients of reproductive potential must agree to follow the contraception requirements.
  7. The patient is capable of understanding and complying with the protocol and has signed the informed consent document. A signed informed consent form must be obtained before any study-specific procedures are performed.
  8. At least 1 measurable lesion according to modified RECIST Version 1.1 (non‑nodal lesions must be ≥1.0 cm in the long axis or ≥double the slide thickness in the long axis) within 21 days prior to the first dose of study drug.
  9. Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments performed at screening.

    • Absolute neutrophil count ≥1000/uL
    • Hemoglobin ≥8 g/dL
    • Platelet count ≥75,000/uL
    • Total bilirubin ≤1.5 x the upper limit of normal (ULN)
    • Aspartate transaminase or alanine transaminase ≤3 x ULN (≤5x ULN in the presence of hepatic metastases)
    • Serum creatinine ≤1.5 x ULN or creatinine clearance ≥50 mL/min based on either urine collection or Cockcroft Gault estimation.
    • Prothrombin time (PT) or international normalized ratio (INR) or partial thromboplastin time ≤1.5 x ULN. Patients on a stable, maintenance regimen of anticoagulant therapy for at least 30 days prior to study drug administration may have PT/INR measurements >1.5 x ULN if, in the opinion of the Investigator, the patient is suitable for the study. An adequate rationale must be provided to the Sponsor prior to randomization.
  10. Resolution of all toxicities from prior therapy to ≤Grade 1 (or baseline) within 1 week prior to the first dose of study drug (excluding alopecia and ≤Grade 3 clinically asymptomatic lipase, amylase, and creatine phosphokinase laboratory abnormalities).

Exclusion Criteria:

  1. Treatment with anticancer therapy, including investigational therapy, or investigational procedures within 14 days or 5 x the half‑life (whichever is longer) prior to the first dose of study drug. For prior biological therapies, eg, monoclonal antibodies with a half‑life longer than 3 days, the interval must be at least 28 days prior to the first dose of study drug.
  2. Prior treatment with DCC-2618
  3. Has a known additional malignancy that is progressing or required active treatment within 3 years of the first dose of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or other in situ cancers.
  4. Patient has known active central nervous system metastases.
  5. New York Heart Association class II - IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.
  6. Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before the first dose of study drug.
  7. Venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within 3 months before the first dose of study drug. Patients with venous thrombotic events ≥3 months before the first dose of study drug on stable anticoagulation therapy are eligible.
  8. 12‑lead electrocardiogram (ECG) demonstrating QT interval corrected by Fridericia's formula >450 ms in males or >470 ms in females at screening or history of long QT interval corrected syndrome.
  9. Left ventricular ejection fraction (LVEF) <50% at screening.
  10. Use of proton-pump inhibitors within 4 days prior to the first dose of study drug. Other medications that increase gastric pH, ie, histamine H2 receptor antagonists and antacids may be taken provided they are not administered within 2 hours before or after administration of study drug.
  11. Use of strong or moderate inhibitors and inducers of cytochrome P450 (CYP) 3A4, including certain herbal medications (eg, St. John's Wort) and consumption of grapefruit or grapefruit juice within 14 days or 5 x the half‑life (whichever is longer) prior to the first dose of study drug.
  12. Use of known substrates or inhibitors of breast cancer resistance protein (BCRP) transporters within 14 days or 5 x the half‑life (whichever is longer) prior to the first dose of study drug.
  13. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug. Following major surgeries, >4 weeks prior to the first dose of study drug, all surgical wounds must be healed and free of infection or dehiscence.
  14. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks.
  15. Known human immunodeficiency virus or hepatitis C infection only if the patient is taking medications that are excluded per protocol, active hepatitis B, or active hepatitis C infection.
  16. If female, the patient is pregnant or lactating.
  17. Known allergy or hypersensitivity to any component of the investigational drug product.
  18. Gastrointestinal abnormalities including but not limited to:

    • inability to take oral medication
    • malabsorption syndromes
    • requirement for intravenous alimentation active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03353753

Hide Hide 36 study locations
Layout table for location information
United States, Arizona
Scottsdale, Arizona, United States, 85260
United States, California
University of Southern California - Norris
Los Angeles, California, United States, 90033
Los Angeles, California, United States, 90095
Stanford, California, United States, 94305
United States, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States, 32224
United States, Georgia
Georgia Cancer Specialists
Atlanta, Georgia, United States, 30341
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New York
New York, New York, United States, 10027
New York, New York, United States, 10065
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Alfred University
Melbourne, Australia
University Hospital Leuven
Leuven, Belgium
Canada, Alberta
Cross Cancer Center
Edmonton, Alberta, Canada
Cross Cancer Centre
Alberta, Canada
Princess Margaret Hospital
Toronto, Canada
Helsinki University Central Hospital
Helsinki, Finland
Institut Bergonié
Bordeaux, France
Le Centre Léon Bérard
Lyon, France
Villejuif, France
Sarcoma Center Brandenburg
Brandenburg, Germany
University Hospital Essen
Essen, Germany
Universitätsmedizin Mannheim
Mannheim, Germany
Istituto Nazionale dei Tumori
Milan, Italy
Università Campus Bio-Medico di Roma
Rome, Italy
Leiden University Medical Center
Leiden, Netherlands
Maria Sklodowska-Curie Memorial Cancer Center
Warsaw, Poland
Singapore, Singapore, 169610
Vall d'Hebron
Barcelona, Spain
Hospitalario Universitario Virgen del Rocío
Seville, Spain
United Kingdom
Royal Marsden
London, United Kingdom
University of Sheffield
Sheffield, United Kingdom
Sponsors and Collaborators
Deciphera Pharmaceuticals LLC
Additional Information:
Layout table for additonal information
Responsible Party: Deciphera Pharmaceuticals LLC Identifier: NCT03353753    
Other Study ID Numbers: DCC-2618-03-001
First Posted: November 27, 2017    Key Record Dates
Last Update Posted: September 16, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases